{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:21:40Z","timestamp":1787869300390,"version":"build-2784847793"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T00:00:00Z","timestamp":1503360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670998"],"award-info":[{"award-number":["81670998"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81321002"],"award-info":[{"award-number":["81321002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Diseases"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:p>Oral submucous fibrosis (<jats:styled-content style=\"fixed-case\">OSMF<\/jats:styled-content>), a potentially malignant oral cavity disorder that causes speech and mastication problems, lacks an established treatment regimen; moreover, no treatment can effectively reverse the course of <jats:styled-content style=\"fixed-case\">OSMF<\/jats:styled-content>. A meta\u2010analysis was conducted to investigate the efficacy of the peripheral vasodilator, pentoxifylline, in the treatment of <jats:styled-content style=\"fixed-case\">OSMF<\/jats:styled-content>. We searched five different databases for studies meeting our eligibility criteria (up to June 30, 2017). Statistical analyses were performed using RevMan 5.3 software. Three randomized controlled trials (247 <jats:styled-content style=\"fixed-case\">OSMF<\/jats:styled-content> patients) were selected. Pentoxifylline increased the objective sign maximal mouth opening (<jats:styled-content style=\"fixed-case\">MMO<\/jats:styled-content>;<jats:styled-content style=\"fixed-case\"> WMD<\/jats:styled-content>: \u22124.59, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: \u22128.65, \u22120.53; <jats:italic>p\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.05) following short\u2010term (under 1\u00a0month; <jats:styled-content style=\"fixed-case\">WMD<\/jats:styled-content>: \u22121.94, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: \u22123.12, \u22120.77; <jats:italic>p\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.05) and long\u2010term (over 1\u00a0month; <jats:styled-content style=\"fixed-case\">WMD<\/jats:styled-content>: \u22125.44, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: \u22126.81, \u22124.07; <jats:italic>p\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.05) application. Pentoxifylline improved the subjective symptom burning sensation (<jats:styled-content style=\"fixed-case\">WMD<\/jats:styled-content>: \u22120.11, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: \u22120.17, \u22120.05; <jats:italic>p\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.05) only following long\u2010term application (<jats:styled-content style=\"fixed-case\">WMD<\/jats:styled-content>: 0.42, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 0.18, 0.96; <jats:italic>p\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.05). The efficacy on <jats:styled-content style=\"fixed-case\">MMO<\/jats:styled-content> and burning sensation increased with time. Although <jats:styled-content style=\"fixed-case\">OSMF<\/jats:styled-content> lacks definitive treatment modalities, our meta\u2010analysis shows that pentoxifylline effectively improves the objective signs and subjective symptoms of <jats:styled-content style=\"fixed-case\">OSMF<\/jats:styled-content> and its therapeutic efficacy increases with time.<\/jats:p>","DOI":"10.1111\/odi.12715","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T08:16:42Z","timestamp":1500884202000},"page":"706-716","source":"Crossref","is-referenced-by-count":27,"title":["Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: A meta\u2010analysis"],"prefix":"10.1111","volume":"24","author":[{"given":"J","family":"Liu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oral Diseases West China Hospital of Stomatology Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases West China Hospital of Stomatology Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3293-0398","authenticated-orcid":false,"given":"Z","family":"Wei","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases West China Hospital of Stomatology Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases West China Hospital of Stomatology Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases West China Hospital of Stomatology Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Dan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases West China Hospital of Stomatology Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases West China Hospital of Stomatology Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6003-7575","authenticated-orcid":false,"given":"L","family":"Jiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases West China Hospital of Stomatology Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10006-010-0225-x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10024-1623"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ebd.6400625"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-012-0824-z"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152812803590028"},{"key":"e_1_2_9_7_1","first-page":"Cd007156","article-title":"Interventions for the management of oral submucous fibrosis","author":"Fedorowicz Z.","year":"2008","journal-title":"Cochrane Database Systematic Review"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.011"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1995.tb01209.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90020-5"},{"key":"e_1_2_9_11_1","first-page":"971","article-title":"Pentoxifylline therapy in the management of oral submucous fibrosis","volume":"12","author":"Mehrotra R.","year":"2011","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2011.10.011"},{"key":"e_1_2_9_13_1","first-page":"3048","article-title":"Spirulina and pentoxyfilline \u2010 a novel approach for treatment of oral submucous fibrosis","volume":"7","author":"Mulk B. S.","year":"2013","journal-title":"Journal of Clinical and Diagnostic Research"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.4103\/0975-8844.143048"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.4317\/jced.51318"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-9290.29865"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2012.07.020"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2016.02.020"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S80576"},{"key":"e_1_2_9_20_1","first-page":"141","article-title":"Comparative evaluation of newer drugs pentoxifylline and spirulina in the management of OSMF","volume":"5","author":"Zwiri A. M. A.","year":"2015","journal-title":"International Journal of Pharmacology & Toxicology"}],"container-title":["Oral Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fodi.12715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/odi.12715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:41:10Z","timestamp":1695490870000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/odi.12715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/odi.12715"],"URL":"https:\/\/doi.org\/10.1111\/odi.12715","archive":["Portico"],"relation":{},"ISSN":["1354-523X","1601-0825"],"issn-type":[{"value":"1354-523X","type":"print"},{"value":"1601-0825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,22]]}}}